• CDT Equity on April 16, 2026 outlined a multi-pathway plan to build shareholder value via a capital-efficient out-licensing model spanning pharma assets, solid-form IP, and AI-driven indication discovery.
• Focus will shift to advancing licensed AstraZeneca compounds into combination therapies or new indications, supported by solid-form and cocrystal programs to improve properties and extend patent life.
• Solid-form IP portfolio will be expanded to create improved versions of existing compounds for partnering with disease-focused drugmakers or capital partners.
• Strategy integrates a 20% stake in private Sarborg to use its Signature Intelligence to generate AI-selected indication packages in minutes for potential licensees.
• Model targets multiple revenue streams from partnering, including upfront payments, milestones, and royalties, while limiting exposure to late-stage clinical development risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CDT Equity Inc. published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information contained therein.